226 related articles for article (PubMed ID: 34058339)
21. Cisplatin binds human copper chaperone Atox1 and promotes unfolding in vitro.
Palm ME; Weise CF; Lundin C; Wingsle G; Nygren Y; Björn E; Naredi P; Wolf-Watz M; Wittung-Stafshede P
Proc Natl Acad Sci U S A; 2011 Apr; 108(17):6951-6. PubMed ID: 21482801
[TBL] [Abstract][Full Text] [Related]
22. Modulating Chemosensitivity of Tumors to Platinum-Based Antitumor Drugs by Transcriptional Regulation of Copper Homeostasis.
Lai YH; Kuo C; Kuo MT; Chen HHW
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772714
[TBL] [Abstract][Full Text] [Related]
23. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells.
Samimi G; Safaei R; Katano K; Holzer AK; Rochdi M; Tomioka M; Goodman M; Howell SB
Clin Cancer Res; 2004 Jul; 10(14):4661-9. PubMed ID: 15269138
[TBL] [Abstract][Full Text] [Related]
24. Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs.
Safaei R; Howell SB
Crit Rev Oncol Hematol; 2005 Jan; 53(1):13-23. PubMed ID: 15607932
[TBL] [Abstract][Full Text] [Related]
25. Copper Chaperone Atox1 Protected the Cochlea From Cisplatin by Regulating the Copper Transport Family and Cell Cycle.
Chen X; Xiang W; Li L; Xu K
Int J Toxicol; 2024; 43(2):134-145. PubMed ID: 37859596
[TBL] [Abstract][Full Text] [Related]
26. Association between polymorphisms in CTR1, CTR2, ATP7A, and ATP7B and platinum resistance in epithelial ovarian cancer.
Li T; Peng J; Zeng F; Zhang K; Liu J; Li X; Ouyang Q; Wang G; Wang L; Liu Z; Liu Y
Int J Clin Pharmacol Ther; 2017 Oct; 55(10):774-780. PubMed ID: 28737129
[TBL] [Abstract][Full Text] [Related]
27. Effect of copper and role of the copper transporters ATP7A and CTR1 in intracellular accumulation of cisplatin.
Matsumoto S; Tanaka T; Kurokawa H; Matsuno K; Hayashida Y; Takahashi T
Anticancer Res; 2007; 27(4B):2209-16. PubMed ID: 17695505
[TBL] [Abstract][Full Text] [Related]
28. Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B.
Samimi G; Katano K; Holzer AK; Safaei R; Howell SB
Mol Pharmacol; 2004 Jul; 66(1):25-32. PubMed ID: 15213293
[TBL] [Abstract][Full Text] [Related]
29. Sec61β controls sensitivity to platinum-containing chemotherapeutic agents through modulation of the copper-transporting ATPase ATP7A.
Abada PB; Larson CA; Manorek G; Adams P; Howell SB
Mol Pharmacol; 2012 Sep; 82(3):510-20. PubMed ID: 22710939
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic Targeting of ATP7B in Ovarian Carcinoma.
Mangala LS; Zuzel V; Schmandt R; Leshane ES; Halder JB; Armaiz-Pena GN; Spannuth WA; Tanaka T; Shahzad MM; Lin YG; Nick AM; Danes CG; Lee JW; Jennings NB; Vivas-Mejia PE; Wolf JK; Coleman RL; Siddik ZH; Lopez-Berestein G; Lutsenko S; Sood AK
Clin Cancer Res; 2009 Jun; 15(11):3770-80. PubMed ID: 19470734
[TBL] [Abstract][Full Text] [Related]
31. Differences in the cellular response and signaling pathways of cisplatin and BBR3464 ([[trans-PtCl(NH3)(2)]2mu-(trans-Pt(NH3)(2)(H2N(CH2)(6)-NH2)2)]4+) influenced by copper homeostasis.
Kabolizadeh P; Ryan J; Farrell N
Biochem Pharmacol; 2007 May; 73(9):1270-9. PubMed ID: 17234160
[TBL] [Abstract][Full Text] [Related]
32. Cisplatin handover between copper transporters: the effect of reducing agents.
Galliani A; Losacco M; Lasorsa A; Natile G; Arnesano F
J Biol Inorg Chem; 2014 Jun; 19(4-5):705-14. PubMed ID: 24789146
[TBL] [Abstract][Full Text] [Related]
33. Functional interactions of Cu-ATPase ATP7B with cisplatin and the role of ATP7B in the resistance of cells to the drug.
Leonhardt K; Gebhardt R; Mössner J; Lutsenko S; Huster D
J Biol Chem; 2009 Mar; 284(12):7793-802. PubMed ID: 19141620
[TBL] [Abstract][Full Text] [Related]
34. Targeting the Copper Transport System to Improve Treatment Efficacies of Platinum-Containing Drugs in Cancer Chemotherapy.
Kuo MT; Huang YF; Chou CY; Chen HHW
Pharmaceuticals (Basel); 2021 Jun; 14(6):. PubMed ID: 34201235
[TBL] [Abstract][Full Text] [Related]
35. Probing the interaction of cisplatin with the human copper chaperone Atox1 by solution and in-cell NMR spectroscopy.
Arnesano F; Banci L; Bertini I; Felli IC; Losacco M; Natile G
J Am Chem Soc; 2011 Nov; 133(45):18361-9. PubMed ID: 21981264
[TBL] [Abstract][Full Text] [Related]
36. The contribution of copper efflux transporters ATP7A and ATP7B to chemoresistance and personalized medicine in ovarian cancer.
Lukanović D; Herzog M; Kobal B; Černe K
Biomed Pharmacother; 2020 Sep; 129():110401. PubMed ID: 32570116
[TBL] [Abstract][Full Text] [Related]
37. Role of copper transporters in the uptake and efflux of platinum containing drugs.
Safaei R
Cancer Lett; 2006 Mar; 234(1):34-9. PubMed ID: 16297532
[TBL] [Abstract][Full Text] [Related]
38. A re-evaluation of the role of hCTR1, the human high-affinity copper transporter, in platinum-drug entry into human cells.
Ivy KD; Kaplan JH
Mol Pharmacol; 2013 Jun; 83(6):1237-46. PubMed ID: 23543413
[TBL] [Abstract][Full Text] [Related]
39. Mechanisms of charge transfer in human copper ATPases ATP7A and ATP7B.
Tadini-Buoninsegni F; Smeazzetto S
IUBMB Life; 2017 Apr; 69(4):218-225. PubMed ID: 28164426
[TBL] [Abstract][Full Text] [Related]
40. Interaction between the anticancer drug Cisplatin and the copper chaperone Atox1 in human melanoma cells.
Palm-Espling ME; Lundin C; Björn E; Naredi P; Wittung-Stafshede P
Protein Pept Lett; 2014; 21(1):63-8. PubMed ID: 23988033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
